SUMOylated DDX3 Promotes HBV Replication and Tumor Growth of Hepatocellular Carcinoma via TRIM28‐DDX3‐KLF4α Signaling Axis
Advanced Science · 2026-11-03
DOI: 10.1002/advs.78603 ↗At a glance
Journal article in Advanced Science, published online on 2026-11-03. Written by Yanfang Yang and 8 co-authors. Institution: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. 59 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, the Strategic Cooperation Project between Sichuan University and Suining Municipal People's Government.
Abstract (original language)
DDX3 has dual biological functions of regulating cell proliferation and antiviral effects. Herein, we focus on SUMOylation‐mediated DDX3 in the interplay from hepatitis B virus (HBV) infection to HBV‐associated hepatocellular carcinoma (HBV‐HCC) progression. We identified dynamic regulation of SUMOylation and DeSUMOylation of DDX3 at four key lysine (K) residues (K81/K208/K215/K564) in response to HBV infection. During the early stage of HBV acute infection, SENP1 interacts with DDX3 to keep DDX3 deSUMOylation for inhibiting HBV replication. During persistent HBV replication, as SENP1 downregulation and HBV polymerase accumulation, DDX3 disassociates with SENP1 to bind with TRIM28, which induces DDX3 SUMOylation. Meanwhile, SUMOylated DDX3 enhances alternative splicing of KLF4 mRNAs to generate KLF4α isoform that involves in Cyclin D1‐mediated cell cycle progression, weakens tumor suppressor function of DDX3 and promotes HBV‐HCC. Moreover, DDX3 expression is positively correlated with KLF4 mRNA, and high DDX3 level with low TRIM28 expression indicates a better overall survival for HBV‐HCC patients. Our findings reveal the dynamic regulation between SUMOylation and deSUMOylation of DDX3, including mediating HBV gene transcription, virus antigen secretion, and cell proliferation. Furthermore, the TRIM28‐DDX3‐KLF4 axis as a novel therapeutic target for HBV‐HCC, exhibiting the dual ability to inhibit tumor progression and disrupt the HBV–host interaction.
Subjects
Author keywords
Authors and institutions
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- Department of Central Laboratory, NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, China.
- Department of Neurology, Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing, China.
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
- The Second Department of Gastrointestinal Surgery, the Affiliated Hospital of North Sichuan Medical College, Sichuan, China.
ORCID profiles: Yanfang Yang, Xiaoli Jin, Samina Ejaz Syed, Shufang Liang
Funding
- National Natural Science Foundation of China
- the Strategic Cooperation Project between Sichuan University and Suining Municipal People's Government
Cite
APA
Yang, Y., Kong, T., Wang, B., Jin, X., Huang, L., Zhang, N., Tang, S., Syed, S. E., & Liang, S. (2026). SUMOylated DDX3 Promotes HBV Replication and Tumor Growth of Hepatocellular Carcinoma via TRIM28‐DDX3‐KLF4α Signaling Axis. Advanced Science. https://doi.org/10.1002/advs.78603
Vancouver
Yang Y, Kong T, Wang B, Jin X, Huang L, Zhang N, et al. SUMOylated DDX3 Promotes HBV Replication and Tumor Growth of Hepatocellular Carcinoma via TRIM28‐DDX3‐KLF4α Signaling Axis. Advanced Science. 2026. doi:10.1002/advs.78603
BibTeX
@article{Yang2026,
author = {Yang, Yanfang and Kong, Ting and Wang, Binghan and Jin, Xiaoli and Huang, Lan and Zhang, Nan and Tang, Siyu and Syed, Samina Ejaz and Liang, Shufang},
title = {SUMOylated DDX3 Promotes HBV Replication and Tumor Growth of Hepatocellular Carcinoma via TRIM28‐DDX3‐KLF4α Signaling Axis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78603}
}
EUVIMED